Developing evolution-resistant drugs for COVID-19.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35880850.
- Also identified by DOI 10.7554/eLife.81334 and PMC identifier 9322998.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Analyzing how mutations affect the main protease of SARS-CoV-2 may help researchers develop drugs that are effective against current and future variants of the virus.
Medical subject headings
- COVID-19 Drug Treatment